Status:
RECRUITING
Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer
Lead Sponsor:
Centre Hospitalier Universitaire Dijon
Conditions:
Metastatic Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Based on the use of the patient's natural defences, immunotherapy mobilizes the immune system to recognize and destroy cancer cells, and it has revolutionized the treatment of lung cancer. However, t...
Eligibility Criteria
Inclusion
- Patients with metastatic NSCLC
- Patient not previously treated
- PD-L1 tumor expression \> 50%, to be treated with immunotherapy alone after validation by a multidisciplinary consultation meeting.
- Patients over 18 years of age
- Patient having given his/her non-opposition
- Patient who speaks and reads French
Exclusion
- Patients previously treated for NSCLC
- Patient with oncogene addiction or a first-line targetable rearrangement
- Patient not suitable for immunotherapy alone
- Patient having received corticosteroid treatment in the 15 days prior to FeNO.
- Patient on inhaled corticosteroid at time of inclusion.
- Blood eosinophilia \> 500 /mm3
- Patient on 24-hour oxygen therapy
- Contraindication to immunotherapy
- Inability to perform FeNO measurement manoeuvres
- Pregnant, parturient or breast-feeding women
- Person under judicial protection (curatorship, guardianship)
- Person subject to limited judicial protection
- Adult unable to express their non-opposition
- Patient refusing to participate in the study
Key Trial Info
Start Date :
September 26 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2027
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT05985330
Start Date
September 26 2023
End Date
September 1 2027
Last Update
June 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Dijon Bourgogne
Dijon, France, 21000